Relapse-related molecular signature in lung adenocarcinomas identifies patients with dismal prognosis

Shuta Tomida, Toshiyuki Takeuchi, Yukako Shimada, Chinatsu Arima, Keitaro Matsuo, Tetsuya Mitsudomi, Yasushi Yatabe, Takashi Takahashi

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

Purpose: In order to aid the development of patient-tailored therapeutics, we attempted to identify a relapse-related signature that allows selection of a group of adenocarcinoma patients with a high probability of relapse. Patients and Methods: Whole-genome expression profiles were analyzed in 117 lung adenocarcinoma samples using microarrays consisting of 41,000 probes. A weighted voting classifier for identifying patients with a relapse-related signature was constructed with an approach that allowed no information leakage during each training step, using 10-fold cross-validation and 100 random partitioning procedures. Results: We identified a relapse-related molecular signature represented by 82 probes (RRS-82) through genome-wide expression profiling analysis of a training set of 60 patients. The robustness of RRS-82 in the selection of patients with a high probability of relapse was then validated with a completely blinded test set of 27 adenocarcinoma patients, showing a clear association of high risk RRS-82 with very poor patient prognosis regardless of disease stage. The discriminatory power of RRS-82 was further validated using an additional independent cohort of 30 stage I patients who underwent surgery at a distinct period of time as well as with the Duke data set on a different platform. Furthermore, completely separate training and validation procedures using another data set recently reported by the Director's Challenge Consortium also successfully confirmed the predictive power of the genes comprising RRS-82. Conclusion: RRS-82 may be useful for identifying adenocarcinoma patients at very high risk for relapse, even those with cancer in the early stage.

Original languageEnglish
Pages (from-to)2793-2799
Number of pages7
JournalJournal of Clinical Oncology
Volume27
Issue number17
DOIs
Publication statusPublished - Jun 10 2009
Externally publishedYes

Fingerprint

Recurrence
Adenocarcinoma
Genome
Adenocarcinoma of lung
Politics
Patient Selection
Genes
Neoplasms
Datasets

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Relapse-related molecular signature in lung adenocarcinomas identifies patients with dismal prognosis. / Tomida, Shuta; Takeuchi, Toshiyuki; Shimada, Yukako; Arima, Chinatsu; Matsuo, Keitaro; Mitsudomi, Tetsuya; Yatabe, Yasushi; Takahashi, Takashi.

In: Journal of Clinical Oncology, Vol. 27, No. 17, 10.06.2009, p. 2793-2799.

Research output: Contribution to journalArticle

Tomida, S, Takeuchi, T, Shimada, Y, Arima, C, Matsuo, K, Mitsudomi, T, Yatabe, Y & Takahashi, T 2009, 'Relapse-related molecular signature in lung adenocarcinomas identifies patients with dismal prognosis', Journal of Clinical Oncology, vol. 27, no. 17, pp. 2793-2799. https://doi.org/10.1200/JCO.2008.19.7053
Tomida, Shuta ; Takeuchi, Toshiyuki ; Shimada, Yukako ; Arima, Chinatsu ; Matsuo, Keitaro ; Mitsudomi, Tetsuya ; Yatabe, Yasushi ; Takahashi, Takashi. / Relapse-related molecular signature in lung adenocarcinomas identifies patients with dismal prognosis. In: Journal of Clinical Oncology. 2009 ; Vol. 27, No. 17. pp. 2793-2799.
@article{5fdeb8ae67b44f1eaf3972db1bf962ea,
title = "Relapse-related molecular signature in lung adenocarcinomas identifies patients with dismal prognosis",
abstract = "Purpose: In order to aid the development of patient-tailored therapeutics, we attempted to identify a relapse-related signature that allows selection of a group of adenocarcinoma patients with a high probability of relapse. Patients and Methods: Whole-genome expression profiles were analyzed in 117 lung adenocarcinoma samples using microarrays consisting of 41,000 probes. A weighted voting classifier for identifying patients with a relapse-related signature was constructed with an approach that allowed no information leakage during each training step, using 10-fold cross-validation and 100 random partitioning procedures. Results: We identified a relapse-related molecular signature represented by 82 probes (RRS-82) through genome-wide expression profiling analysis of a training set of 60 patients. The robustness of RRS-82 in the selection of patients with a high probability of relapse was then validated with a completely blinded test set of 27 adenocarcinoma patients, showing a clear association of high risk RRS-82 with very poor patient prognosis regardless of disease stage. The discriminatory power of RRS-82 was further validated using an additional independent cohort of 30 stage I patients who underwent surgery at a distinct period of time as well as with the Duke data set on a different platform. Furthermore, completely separate training and validation procedures using another data set recently reported by the Director's Challenge Consortium also successfully confirmed the predictive power of the genes comprising RRS-82. Conclusion: RRS-82 may be useful for identifying adenocarcinoma patients at very high risk for relapse, even those with cancer in the early stage.",
author = "Shuta Tomida and Toshiyuki Takeuchi and Yukako Shimada and Chinatsu Arima and Keitaro Matsuo and Tetsuya Mitsudomi and Yasushi Yatabe and Takashi Takahashi",
year = "2009",
month = "6",
day = "10",
doi = "10.1200/JCO.2008.19.7053",
language = "English",
volume = "27",
pages = "2793--2799",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "17",

}

TY - JOUR

T1 - Relapse-related molecular signature in lung adenocarcinomas identifies patients with dismal prognosis

AU - Tomida, Shuta

AU - Takeuchi, Toshiyuki

AU - Shimada, Yukako

AU - Arima, Chinatsu

AU - Matsuo, Keitaro

AU - Mitsudomi, Tetsuya

AU - Yatabe, Yasushi

AU - Takahashi, Takashi

PY - 2009/6/10

Y1 - 2009/6/10

N2 - Purpose: In order to aid the development of patient-tailored therapeutics, we attempted to identify a relapse-related signature that allows selection of a group of adenocarcinoma patients with a high probability of relapse. Patients and Methods: Whole-genome expression profiles were analyzed in 117 lung adenocarcinoma samples using microarrays consisting of 41,000 probes. A weighted voting classifier for identifying patients with a relapse-related signature was constructed with an approach that allowed no information leakage during each training step, using 10-fold cross-validation and 100 random partitioning procedures. Results: We identified a relapse-related molecular signature represented by 82 probes (RRS-82) through genome-wide expression profiling analysis of a training set of 60 patients. The robustness of RRS-82 in the selection of patients with a high probability of relapse was then validated with a completely blinded test set of 27 adenocarcinoma patients, showing a clear association of high risk RRS-82 with very poor patient prognosis regardless of disease stage. The discriminatory power of RRS-82 was further validated using an additional independent cohort of 30 stage I patients who underwent surgery at a distinct period of time as well as with the Duke data set on a different platform. Furthermore, completely separate training and validation procedures using another data set recently reported by the Director's Challenge Consortium also successfully confirmed the predictive power of the genes comprising RRS-82. Conclusion: RRS-82 may be useful for identifying adenocarcinoma patients at very high risk for relapse, even those with cancer in the early stage.

AB - Purpose: In order to aid the development of patient-tailored therapeutics, we attempted to identify a relapse-related signature that allows selection of a group of adenocarcinoma patients with a high probability of relapse. Patients and Methods: Whole-genome expression profiles were analyzed in 117 lung adenocarcinoma samples using microarrays consisting of 41,000 probes. A weighted voting classifier for identifying patients with a relapse-related signature was constructed with an approach that allowed no information leakage during each training step, using 10-fold cross-validation and 100 random partitioning procedures. Results: We identified a relapse-related molecular signature represented by 82 probes (RRS-82) through genome-wide expression profiling analysis of a training set of 60 patients. The robustness of RRS-82 in the selection of patients with a high probability of relapse was then validated with a completely blinded test set of 27 adenocarcinoma patients, showing a clear association of high risk RRS-82 with very poor patient prognosis regardless of disease stage. The discriminatory power of RRS-82 was further validated using an additional independent cohort of 30 stage I patients who underwent surgery at a distinct period of time as well as with the Duke data set on a different platform. Furthermore, completely separate training and validation procedures using another data set recently reported by the Director's Challenge Consortium also successfully confirmed the predictive power of the genes comprising RRS-82. Conclusion: RRS-82 may be useful for identifying adenocarcinoma patients at very high risk for relapse, even those with cancer in the early stage.

UR - http://www.scopus.com/inward/record.url?scp=67649965344&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649965344&partnerID=8YFLogxK

U2 - 10.1200/JCO.2008.19.7053

DO - 10.1200/JCO.2008.19.7053

M3 - Article

VL - 27

SP - 2793

EP - 2799

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 17

ER -